Some tumor cells have a change in the MTAP gene. This change makes the protein PRMT5 bind the molecule MTA instead of the normal molecule SAM. That difference creates a weakness that drugs could use to kill cancer cells while sparing normal cells.
To test this idea, researchers used a biosensor method based on Promega's NanoBRET technology. The Oxford team developed a cell‑permeable BRET probe called CBH-002 that reports when drugs bind PRMT5 in live cells. The findings suggest it may be possible to design drugs that act only when PRMT5 is bound to MTA, limiting activity to tumor tissue.
Difficult words
- tumor — A mass of abnormal body cells.
- gene — A part of DNA that gives instructions.
- protein — A molecule made by cells with jobs.
- bind — To join or stick to something.
- biosensor — A device or method that detects molecules.
- probe — A small tool used to find or measure.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you prefer a drug that kills cancer cells but leaves normal cells alive? Why?
- How can a biosensor like CBH-002 help scientists?
- Why is it good to test drugs in live cells before other studies?
Related articles
Protein linked to chemotherapy resistance in ovarian cancer
Scientists found that some ovarian cancer cells survive cisplatin chemotherapy by stabilising their internal scaffold. They identified a protein that can be blocked in laboratory tests to restore the drug's effectiveness and may serve as a biomarker.
